Cellectis S.A(NASDAQ:CLLS) 
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an all...
Website: http://www.cellectis.com
Founded: 1999
Full Time Employees: 253
Sector: Healthcare
Industry: Biotechnology
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2025-04-04
P
O 1.16
H 1.18
L 1.10
C 1.15
V 126,358
10EMA 1.15
20EMA 1.15
60EMA 1.15
120EMA 1.15
250EMA 1.15